Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BMegaPro Biomedical Co., Ltd. 〉MPB1514: an intravenous iron drug for iron deficient anemia (IDA)

MPB1514: an intravenous iron drug for iron deficient anemia (IDA)

MPB1514: an intravenous iron drug for iron deficient anemia (IDA)

MPB1514 is a pegylated iron oxide nanoparticles product. MPB1514 have the potential to provide:
1. Higher dose of intravenous iron, shorter time to complete the course of treatment, thus to enhance the patient compliance.
2. Compared to the dextran excipient on other intravenous iron products, MPB1514, without dextran, is expected to provide lower chance for hypersensitivity side effect. MPB1514 may be a safer drug candidate for the iron deficient anemia treatment.

Request for Collaboration
Overview
MPB1514: an intravenous iron drug for iron deficient anemia (IDA)
MPB1514 is a pegylated iron oxide nanoparticles product
 
Iron deficient Anemia:
With the aging society and growing trend of diabetic population, the occurrence of chronic kidney disease (CKD) is increasing. It showed that there are about 10% of population bearing with chronic kidney disease, even in the developed countries. Among them, there are 25-30% of CKD patients also suffered from iron deficient anemia (IND/CKD patients), but oral iron treatment failed or responded poorly. The current treatment strategy is to provide intravenous iron to the patients. Due to the high serum iron ion may occurred and induced ion toxicity, the patients will be treated with low dose of intravenous iron for 5-10 times of treatment to complete a course of treatment.
 
With that in mind, MPB1514 have the potential to provide:
Higher dose of intravenous iron, shorter time to complete the course of treatment, thus to enhance the patient compliance.
Compared to the dextran excipient on other intravenous iron products, MPB1514, without dextran, is expected to provide lower chance for hypersensitivity side effect. MPB1514 may be a safer drug candidate for the iron deficient anemia treatment.
 
The phase 1 trial of MPB1514 has been completed at 2016.
Features
MPB1514 have the potential to provide:
1.    Higher dose of intravenous iron, shorter time to complete the course of treatment, thus to enhance the patient compliance.
2.    Compared to the dextran excipient on other intravenous iron products, MPB1514, without dextran, is expected to provide lower chance for hypersensitivity side effect. MPB1514 may be a safer drug candidate for the iron deficient anemia treatment.
C.    The phase 1 trial of MPB1514 has been completed at 2016.
Application
Iron deficient Anemia:
With the aging society and growing trend of diabetic population, the occurrence of chronic kidney disease (CKD) is increasing. It showed that there are about 10% of population bearing with chronic kidney disease, even in the developed countries. Among them, there are 25-30% of CKD patients also suffered from iron deficient anemia (IND/CKD patients), but oral iron treatment failed or responded poorly. The current treatment strategy is to provide intravenous iron to the patients. Due to the high serum iron ion may occurred and induced ion toxicity, the patients will be treated with low dose of intravenous iron for 5-10 times of treatment to complete a course of treatment.
People who like this also like
  • PhytoHealth EnerCharge® DrinkPhytoHealth EnerCharge® Drink
  • ANTISURASE B-96ANTISURASE B-96
  • ApoX Anti-virus sprayApoX Anti-virus spray
  • Horus DEC 200 Digital hand-held Fundus cameraHorus DEC 200 Digital hand-held Fundus camera
  • Atopic dermatitis genetic screeningAtopic dermatitis genetic screening
  • Synovial Fluid SupplementSynovial Fluid Supplement
  • Revision Femoral HeadRevision Femoral Head
  • HEPAVASE A-96 (TMB)HEPAVASE A-96 (TMB)
  • Facial Dermal ImplantFacial Dermal Implant
  • Anatomic Precision PSI HTOAnatomic Precision PSI HTO